ij

Ħ

ĸ,

			$\overline{}$
Please type a plus sign (+)	inside this box	-	+

PTO/SB/05 (03-01) Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

1000.06.003 Attorney Docket No. AGATA, ET AL. First Inventor **Tumor Chemopotentiation Using Isocoumarin Derivatives** Title

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Express Mail Label No. ET163419644US Assistant Commissioner for Patents **APPLICATION ELEMENTS** ADDRESS TO: **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents. Washington, D.C. 20231 Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table o (Submit an original, and a duplicate for fee processing) Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) Computer Readable Form (CRF) a. [Total Pages 3. Specification (preferred arrangement set forth below) Specification Sequence Listing on: - Descriptive title of the invention i. CD-ROM or CD-R (2 copies); or - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix Statements verifying identity of above copies - Background of the Invention - Brief Summary of the Invention **ACCOMPANYING APPLICATION PARTS** - Brief Description of the Drawings (if filed) Assignment Papers (cover sheet & document(s)) - Detailed Description 9. - Claim(s) 37 CFR 3.73(b) Statement Power of Attorney 10. - Abstract of the Disclosure (when there is an assignee) English Translation Document (if applicable) 14 Drawing(s) (35 U.S.C. 113) [Total Sheets Copies of IDS Information Disclosure 12. Statement (IDS)/PTO-1449 Citations 6 [Total Pages Oath or Declaration 13. Preliminary Amendment Newly executed (original or copy) Return Receipt Postcard (MPEP 503) 14. (Should be specifically itemized) Copy from a prior application (37 CFR 1.63(d)) Certified Copy of Priority Document(s) (for continuation/divisional with Box 18 completed) 15. (if foreign priority is claimed) **DELETION OF INVENTOR(S)** Nonpublication Request under 35 U.S.C. 122 16. (b)(2)(B)(i). Applicant must attach form PTO/SB/35 Signed statement attached deleting inventor(s) or its equivalent. named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 17. Other: Application Data Sheet. See 37 CFR 1.76 If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, 18. or in an Application Data Sheet under 37 CFR 1.76: Continuation-in-part (CIP) of prior application No.: 09/794,417 Divisional Continuation Group / Art Unit: 1614 Prior application information: Examiner _Ierome D. Goldberg For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. CORRESPONDENCE ADDRESS or Correspondence address below X Customer Number or Bar Code Label (Insert Customer I PATENT TRADEMARK OFFICE Name Address Zip Code City State Fax Telephone Country Registration No. (Attorney/Agent) Name (Print/Type) STEPHEN J. MOLON Date Signature

Burden Hour Statement: This form is estimated to take 0.2 boors to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Fox Patent Application, Washington, DC 20231.

1
400
F. 10
E.A.
W.W.
No.
Ħ,
, h
H
Age Can Can Will
Age Can Can Will
Time Time Time

FEE TRANSMITTAL		Complete if Known				
for FY 20		Application Number				
101 F 1 20	<i>1</i> 02	Filing Date	02/22/02			
Patent fees are subject to annu	al revision.	First Named Inventor	AGATA, ET AL.			
Applicant claims small entity status.	See 37 CFR 1.27	Examiner Name				
*	1.7	Group Art Unit				
TOTAL AMOUNT OF PAYMENT	\$412.00	Attorney Docket No.	1000.06.003			

METHOD OF PAYMENT (check all that apply)				FE	E CALCULATION (continued)	
Check Credit card Money Other None		DITIO	ONAL I	FEES Entity		
Deposit Account:	Fee	Fee	Fee	Fee	_	Fee Paid
Deposit Account 501786	Code 105	(\$) 130	Code 205	(\$) 65	Surcharge - late filing fee or oath	
Number Deposit	127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
Account Name ILEX ONCOLOGY, INC.	139	130	139	130	Non - English specification	
The Commissioner is authorized to: (check all that apply)	147	2,520	147	2,520	For filing a request for ex parte reexamination	
Charge fee(s) indicated below Credit any overpayments	112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
Charge any additonal fee(s) during the pendency of this application	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner	
Charge fee(s) indicated below, except for the filing fee	115	110	215	55	action Extension for reply within first month	
to the above identified deposit account.	116	400	216	200	Extension for reply within second month	
FEE CALCULATION	117	920	217	460	Extension for reply within third month	
BASIC FILING FEE Large Entity Small Entity	118	1,440	218	720		
Fee Fee Fee Fee Description	128	1,960	228	980	Extension for reply within fifth month	
Code (\$) Code (\$) Fee Paid 101 740 201 370 Utility filing fee 370.00	119	320	219	160	Notice of Appeal	
106 330 206 165 Design filing fee	120	320	220	160	Filing a brief in support of an appeal	
107 510 207 255 Plant filing fee	121	280	221	140	Request for oral hearing	
108 740 208 370 Reissue filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding	
114 160 214 80 Provisional filing fee	140	110	240	55	Petition to revive - unavoidable	
SUBTOTAL (1) \$370.00	141	1,280	241	640		
2. EXTRA CLAIM FEES FOR UTILITY AND	142	1,280	242	640	·	
Fee from Extra Claims below Fee Paid	143	460	243	230		
Total Claims 20 -20**= 0 X = 0.00	144	620	244		Plant issue fee	
Independent 4 - 3** = 1 X 42.00 = 42.00	122	130	122	130		
Claims	123	50	123		Processing fee under 37 CFR § 1.17(q)	
Large Entity Small Entity	126	180	126	180	Submission of Information Disclosure Statement	
Fee Fee Fee Fee Description Code (\$) Code (\$)	581	40	581	40	Recording each patent assignment per property (times number of properties)	
103 18 203 9 Claims in excess of 20	146	740	246	370	Filing a submission after final rejection	
102 84 202 42 Independent claims in excess of 3	149	740	249	370	(37 CFR § 1.129(a)) For each additional invention to be examined	
104 280 204 140 Multiple dependent claim, if not paid					(37 CFR § 1.129(b))	
109 84 209 42 ** Reissue independent claims over original patent	179	740			Request for Continued Examination (RCE)	
110 18 210 9 ** Reissue claims in excess of 20	169	900	169	900	Request for expedited examination of a design application	
and over original patent	Oth	er fee ((specify)			
SUBTOTAL (2) \$42.00						
**or number previously paid, if greater; For Reissues, see above	*Red	duced b	oy Basic	Filing	Fee Paid SUBTOTAL (3)	
SUBMITTED BY	9				Complete (if applicable)	
Name (Pnnt/Type) STEPHEN J. MOLONEY			ration No y/Agent)	D.	44947 Telephone 210 949 82	273
Signature	7				Date Felt 22 &	002

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Stephen J. Moloney, Ph.D., J.D.

Associate Counsel Intellectual Property

(210) 949-8273 phone (210) 949-8261 fax smoloney@ilexonc.com

February 22, 2002

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

VIA EXPRESS MAIL # ET163419644US

Patent Application for: TUMOR CHEMOPOTENTIATION USING ISOCOUMARIN DERIVATIVES Inventors: Agata & Kharbanda

Dear Sir:

Enclosed please find the following in the above-referenced matter:

- 1. Utility Patent Application Transmittal Sheet;
- 2. Fee Transmittal for FY 2002 plus 1 copy;
- 3. Utility Patent Application;
- 4. 14 sheets of drawings; and
- 5. Return receipt postcard.

Commissioner is hereby authorized to charge the filing fee for the above referenced application, in the amount of \$412.00, to Deposit Account No. 501786. Further, under 37 CFR §§ 1.16 and 1.17, Commissioner is authorized to charge any deficiency in fees in this matter to the same deposit account. Please associate this file with Customer No. 31076.

Respectfully submitte

Stephen J. Moloney Reg. No. 44,947

Serial No.	Filing Date 02/22/02	Examiner	Group Art Unit
ention: TUMOR CH	EMOPOTENTIATION USING I	SOCOUMARIN DERIVATIVES	
	e following correspondence:		
	(Identify type	of correspondence)	
37 CFR 1.10 in an env	velope addressed to: The Assista 2/02	ice "Express Mail Post Office to A	
(Date		FRANCES WINE (Typed or Printed Name of Person Mai	
		(Signature of Person Mailing Co	

Note: Each paper must have its own certificate of mailing.

CERTIFICATE OF I	MAILING BY "EXPRESS NET AL.	MAIL" (37 CFR 1.10)		Docket No. 1000.06.003
Serial No.	Filing Date 02/22/02	Examiner		Group Art Unit
Invention: TUMOR CH	IEMOPOTENTIATION USING I	SOCOUMARIN DERIVATIV	VES	
	e following correspondence: PATENT APP	LICATION C	1P	
Y	(Identify type	of correspondence)		
** ***	th the United States Postal Servi		, to Ad.	draccaall carvina under
is being deposited with 37 CFR 1.10 in an enterpolation (Date of Control of C		۸		
ing and		(Typed or Printed Name of Perso	on Mailin	g Correspondence)
पिताम पीतार्थि प्राप्ता पितास		(Signature of Person Mail		
TILL ON		ET16341! ("Express Mail" Maili		
	Note: Each paper must h	ave its own certificate of mailing.		

RTIFICATE OF I	MAILING BY "EXPRESS I ET AL.	MAIL" (37 CFR 1.10)	Docket No. 1000.06.003
Serial No.	Filing Date 02/22/02	Examiner	Group Art Unit
ntion: TUMOR CH	EMOPOTENTIATION USING I	SOCOUMARIN DERIVATIVI	ES
	e following correspondence:	nal Drawing	5
being deposited with		of correspondence)	
being deposited with	n the United States Postal Servi	ce "Express Mail Post Office t	o Addressee" service under
-	relope addressed to: The Assista		
7 CFR 1.10 in an env	relope addressed to: The Assista		Washington, D.C. 20231 on
7 CFR 1.10 in an env	relope addressed to: The Assista	nt Commissioner for Patents, FRANCES WI (Typed or Printed Nume of Person I	Washington, D.C. 20231 on NKLER Mailing Correspondence)
7 CFR 1.10 in an env	relope addressed to: The Assista	FRANCES WI (Typed or Printed Name of Person Mailing ET1634196	Washington, D.C. 20231 on NKLER Mailing Correspondence) g Correspondence) 44US
7 CFR 1.10 in an env	relope addressed to: The Assista	TRANCES WI (Typed or Printed Nume of Person in Signature of Person Mailing)	Washington, D.C. 20231 on NKLER Mailing Correspondence) g Correspondence) 44US
7 CFR 1.10 in an env	relope addressed to: The Assista	TRANCES WI (Typed or Printed Numg of Person Mailing ET1634196 ("Express Mail" Mailing	Washington, D.C. 20231 on NKLER Mailing Correspondence) g Correspondence) 44US
37 CFR 1.10 in an env	relope addressed to: The Assista	FRANCES WI (Typed or Printed Name of Person Mailing ET1634196	Washington, D.C. 20231 of MKLER Mailing Correspondence) g Correspondence) 44US